Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Outlook Therapeutics, Inc. entered into Engagement Letter with M.S. Howells & Co. (the “Placement Agent”) (effective 2022-12-22).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- M.S. Howells & Co. (the “Placement Agent”)
- Effective
- 2022-12-22
Exact text from the filing
Pursuant to a letter agreement dated as of December 22, 2022 (the “Engagement Letter”), the Company engaged M.S. Howells & Co. (the “Placement Agent”) to act as placement agent with respect to certain accredited investors in the Offering.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Outlook Therapeutics, Inc. entered into Purchase Agreements with certain institutional and accredited investors, including GMS Ventures and Investments, an affiliate of the Company valued at approximately $25 million (effective 2022-12-23).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain institutional and accredited investors, including GMS Ventures and Investments, an affiliate of the Company
- Value
- approximately $25 million
- Effective
- 2022-12-23
Exact text from the filing
On December 23, 2022, Outlook Therapeutics, Inc. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain institutional and accredited investors (the “Purchasers”), including GMS Ventures and Investments, an affiliate of the Company, pursuant to which the Company agreed to sell and issue, in a registered direct offering, an aggregate of 28,460,831 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at a purchase price of $0.8784 per share, for aggregate gross proceeds to the Company of approximately $25 million
View on SEC.gov